Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P478 | DOI: 10.1530/endoabs.35.P478

ECE2014 Poster Presentations Diabetes therapy (40 abstracts)

Hypogonadal men with cardiovascular diseases benefit from long-term treatment with testosterone undecanoate: observational data from a registry study

Farid Saad 1, , Ahmad Haider 3 , Gheorghe Doros 4 & Abdulmaged Traish 5


1Global Medical Affairs Men’s Healthcare, Bayer Pharma, Berlin, Germany; 2School of Medicine, Gulf Medical University, Ajman, United Arab Emirates; 3Private Urology Practice, Bremerhaven, Germany; 4Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, Massachusetts, USA; 5Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, Massachusetts, USA.


Background: Hypogonadism is associated with cardiometabolic risk. Studies suggest that hypogonadism increases the risk of all-cause and cardiovascular mortality. While some short-term studies have been performed in men with CVD, there are no data on long-term effects of testosterone replacement therapy (TRT) in men with CVD.

Methods: In a prospective, cumulative, observational registry study from a single urologist’s office, 300 men with testosterone ≤12.1 nmol/l received TU injections for upto 6 years. In this subgroup analysis, 68 men with a previous diagnosis of coronary artery disease (CAD; n=40) and/or a history of myocardial infarction (MI; n=40) were analyzed.

Results: Mean age was 60.76±4.94 years. 68 men were included for 2 years, 59 for 3 years, 54 for 4 years, 44 for 5 years, and 28 for 6 years. Declining numbers reflect the nature of the registry but not drop-out rates.

Weight (kg) decreased from 115.07±13.71 to 92.5±9.64. Waist circumference (cm) decreased from 112.07±7.97 to 99.89±6.86. BMI decreased from 37.27±4.45 to 30.14±3.21 (P<0.0001 for all). Mean weight loss was 17.05±0.57%. Fasting glucose decreased from 108.74±17.08 to 96.0±1.92 mg/dl, HbA1c from 7.81±1.17 to 6.2±0.62% (P<0.0001 for both). Total cholesterol decreased from 304.66±34.09 to 189.32±9.68, LDL from 184.28±37.51 to 134±27.91, triglycerides from 308.38±56.3 to 187.71±8.67 mg/dl (P<0.0001 for all). HDL increased slightly. The total cholesterol:HDL ratio declined from 5.16±1.55 to 3.15±0.87 (P<0.0001). Systolic BP decreased from 167.82±11.01 to 142.36±10.62, diastolic BP from 102.28±8.23 to 81.25±8.07 mmHg (P<0.0001 for both). Pulse pressure declined from 65.54±5.24 to 61.11±4.66 (P<0.0001).

The minimum number of injections was 9, maximum 26. In no patient TRT was discontinued or interrupted. There were no major cardiovascular events during the observation time.

Conclusion: TRT in hypogonadal men with CVD was well tolerated and resulted in significant and sustained improvements of cardiometabolic risk factors. Adherence to TRT was excellent.

Article tools

My recent searches

No recent searches.